Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Fentanyl TAIFUN for breakthrough cancer pain in opioid-maintained patients
2008-007964-40Phase 3Terminated
- Sponsor
- Akela Pharma Inc.
- Start
- Dec 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fentanyl in breakthrough cancer pain (BTcP) (2 arms), sponsored by Akela Pharma Inc. Started Dec 2008; status: terminated.
02
Drugs
fentanyl
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on 2008-007964-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007964-40.